Pharma stocks have underperformed the market in the fourth quarter with the Stoxx Europe 600 Health Care index--which is heavily dominated by Europe's six largest pharma companies--down 9.4% against a ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...

H.C. Wainwright analyst Edward White reiterated a Buy rating on Valneva (VALN – Research Report) today and set a price target of $18.00.Invest ...

The pharmaceutical industry could generate more than $1.2 trillion in global sales in 2025, according to Statista. The cancer segment alone is expected to generate $208 billion in sales this year.

SINGAPORE: The updated JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be offered under the national vaccination programme at ...

Adar Poonawalla, CEO, Serum Institute of India talks to Arijit Barman about a range of issues including the impact of Trump’s ...

President Donald Trump's boost to AI demand hopes is outweighing fresh tariff threats on China and the EU, as earnings season ...

In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

Dylan Lewis: We're talking three stocks down bad. Motley Fool Money starts down. I'm Dylan Lewis, I'm joined over the ...